Spiegel R. — Psychopharmacology: an introduction :: Электронная библиотека попечительского совета мехмата МГУ

Главная Ex Libris Книги Журналы Статьи Серии Каталог Wanted Загрузка ХудЛит Справка Поиск по индексам Поиск Форум

Авторизация

Поиск по указателям

Spiegel R. — Psychopharmacology: an introduction

Обсудите книгу на научном форуме

Нашли опечатку?
Выделите ее мышкой и нажмите Ctrl+Enter

Название: Psychopharmacology: an introduction

Автор: Spiegel R.

Аннотация:

Describes the latest advances in psychopharmacology - one of the most rapidly developing fields in modern science. This latest edition has been updated to cover new developments in drug therapy and research including newly introduced antipsychotics, antidepressants and antidementia drugs. Sections on the treatment of depression and dementia have been revised to include new developments in treatment strategies. It will be welcomed for its essentially clinical and psychological approach to modern pharmaceuticals, their therapeutic uses and limitations, adverse reactions and future directions for research.

Язык:

Рубрика: Медицина и здравоохранение/

Статус предметного указателя: Готов указатель с номерами страниц

ed2k: ed2k stats

Издание: fouth edition

Год издания: 2003

Количество страниц: 400

Добавлена в каталог: 11.12.2005

Операции: Положить на полку | Скопировать ссылку для форума | Скопировать ID

Предметный указатель

Depression, bipolar, acute, treatments during      279
Depression, bromine treatment      36
Depression, catecholamine hypothesis of      118—119 (120)
Depression, cognitive changes in      234—235
Depression, drug therapy and psychotherapy      279—290
Depression, endogenous      9—10 42-^13 81 286 288
Depression, interpersonal therapy studies      286—288
Depression, involutional      10
Depression, late      10
Depression, maintenance therapy      277—278
Depression, manic-depressive      278
Depression, melancholic subtype of      234
Depression, menopausal      42
Depression, models of      132—134
Depression, mood stabilizers in      278—279
Depression, neurotic      287
Depression, psychogenic      9—10
Depression, scales for      197—199
Depression, serotonin hypothesis of      118—120
Depression, situative      286 288
Depression, social skills therapy      288—289
Depression, somatogenic      9—11
Depression, studies of      40 152 166—167 169 177 186 263
Depression, treatment by antidepressants      1 16 18 275—291
Depression, treatment by antidepressants, depressive episodes      275—277
Depression, treatment by antidepressants, newer generation of      271—277
Depression, treatment by antidepressants, preventive therapy      278
Depression, unipolar      10 148 278 287 289
Depressive episodes      275—277
Desipramine      10 11 161 236
Desipramine and bipolar disorder      279
Desipramine, action spectra of      12
Desipramine, efficacy of      13
Desoxyn $\textregistered$       25
Desyrel $\textregistered$       11
Dexedrine $\textregistered$       25
Dextroamphetamine      25
Dextrostat $\textregistered$       25
Diabetes      194
Diabetes, insipidus, nephrogenic      17
Diagnosis, correct      153—155
Diagnosis, reliability      153—154
Diagnosis, validity      153—154
Diagnostic and Statistical Manual (DSM) of Mental Disorders      15
Diagnostic and Statistical Manual (DSM) of Mental Disorders, DSM-III      276
Diagnostic and Statistical Manual (DSM) of Mental Disorders, DSM-III, depression criteria in      276
Diagnostic and Statistical Manual (DSM) of Mental Disorders, DSM-III-R      239 249
Diagnostic and Statistical Manual (DSM) of Mental Disorders, DSM-IV      197 201 246—247 291
Diagnostic and Statistical Manual (DSM) of Mental Disorders, DSM-IV, categories of stress disorder      291—292
Diagnostic and Statistical Manual (DSM) of Mental Disorders, DSM-IV, most common drug uses      291
Diarrhea      14 17 23 239 256 276
Diazepam      19 95 161 242—243 293 295
Dibenzepine      11 12 83
Diclofenac      257
Dietary deficiencies, and dementia      253
Differential, semantic      63—64
Digit Symbol Substitution Test      69 239
Dihydroxyphenylacetic acid, $^{18}F$ labelled ( $[^{18}F]$ dopa)      220
Dipiperon $\textregistered$       5
Dipotassium      19
Discontinuation trials      267—269
Disorientation, states of      20
Distress      21
distribution      see ADME
Dizziness      13—14 25 88 256 267
DNA      139
Dogmatic      5
Donepezil      26 53—54 89 126 255—256
Dopamine(DA)      54 110—111 113—115 125—127 131 215
Dopamine(DA), agonist      96
Dopamine(DA), antagonists      90 96 127
Dopamine(DA), hypofunction      115
Dopamine(DA), receptors      52
Dopamine(DA), transporters, radio-labelling of      220
Dopaminergic function      58
Doping, in sport      24
Doral $\textregistered$       19
Dose      5
Dose of antipsychotics      264—269
Dose of antipsychotics, during long-term treatments      265—266
Dose, concentration-controlled      193
Dose, escalation      162
Dose, finding      191—192
Dose, fixed      191—192
Dose, initial and escalation      185—186
Dose, maximum tolerated (MTD)      186
Dose, multiple, early      186
Dose, no effect      185
Dose, proportionality      159
Dose, titration      192—193
Dose-effect relationships      265
Dose-response, relationship      248
Dose-response, trials      190—191
Dothiepin, effects of      79—80 82
Double vision      17
Doxepin      10—11 13 82 236
Doxepin, action spectra of      12
Dreams, vivid      14
Driving      162
Drowsiness      2 88
DRS      see Dementia Rating Scale
Drugs for Alzheimer's disease      50 53—54
Drugs, 'tailored'      122
Drugs, actions of      97
Drugs, addiction to      24
Drugs, anti-inflammatory      3 257—258
Drugs, anti-inflammatory, non-steroidal (NSAIDsj      257—258
Drugs, antianxiety      241—246
Drugs, antidementia      2—3 25—26 53 55 94 96 149 252—259
Drugs, antidepressant      1—3 (2) 9—15 41—44 234—241
Drugs, antiepileptic      161 241
Drugs, antipsychotic      1—9 (2) 42 228—234
Drugs, anxiolytic      2—3 17—23 44 245—246
Drugs, atypical antipsychotic      50—52
Drugs, calculating value of      302—315
Drugs, calculating value of, cost-benefit analysis      308 312—313
Drugs, calculating value of, cost-effectiveness analysis      308—309
Drugs, calculating value of, cost-minimization analysis      308 312
Drugs, calculating value of, cost-utility analysis      308 309—312
Drugs, cholinergic      55—56 88—89 255—256
Drugs, comparator      174—178
Drugs, comparator, dose selection      177—178
Drugs, development, phases of      183—194 (184)
Drugs, disposition      224—225
Drugs, disposition, assessment by MRS      225—226
Drugs, effects, behavioral, neurophysiological parameters      70—76
Drugs, effects, behavioral, recording methods for      64—70
Drugs, effects, behavioral, recording methods for, performance tests      65
Drugs, effects, clinical understanding and predicting      94—96
Drugs, effects, differential      89—91
Drugs, effects, subjective      61
Drugs, effects, subjective, recording methods for      62—64
Drugs, effects, subjective, recording methods for, adjective checklists      63—64
Drugs, effects, subjective, recording methods for, free descriptions      62
Drugs, effects, subjective, recording methods for, self-rating scales      62
Drugs, effects, subjective, recording methods for, structured questioning      62
Drugs, effects, subjective, recording methods for, symptom checklists      62—63
Drugs, experiments on, assessment methods in      61—76
Drugs, experiments on, findings on healthy volunteers      76—89
Drugs, hallucinogenic      323
Drugs, hypnotic      2—3 17—23 35—36 58 82—85
Drugs, interactions      322
Drugs, multifunctional      127
Drugs, names, generic/trade      5
Drugs, overdosage, and dementia      253
Drugs, prescribing of      321—322
Drugs, psychotropic      61—62 64 91 94 96 323
Drugs, psychotropic, and psychology      323—324
Drugs, psychotropic, behavioral effects      62
Drugs, psychotropic, classification on EEG criteria      72

Drugs, psychotropic, neurophysiological effects      62
Drugs, psychotropic, plant derived      27
Drugs, psychotropic, subjective effects of      61—64
Drugs, safety, long-term      194
Drugs, social      2
Drugs, therapy and psychotherapy      269—274 294—295 297—299
Drugs, therapy and psychotherapy, comparative studies      269—270
Drugs, therapy and psychotherapy, of depression      279—290
Drugs, therapy and psychotherapy, studies of      270—274. 280—283
Drugs, therapy and psychotherapy, with cognitive therapy      283—286
Drugs, therapy and psychotherapy, with interpersonal therapy      287—288
Dry mouth      7 8 13—14 18 76 240
DSM      see Diagnostic and Statistical Manual of Mental Disorders
DTS      see Davidson Trauma Scale
Duloxetine      127 172
Duration of treatment with antipsychotics      264—269
Duration of treatment with antipsychotics, compliance      266—267
Dysarthria      17
Dyskinesia      7 8 25 114
Dyskinesia, tardive      7 265
Dyskinesia, tardive, and neuroleptics      7—9
Dysphoria      21 25
Dysphoria, drug-induced      77
Dysphoria, premenstrual      192
Dystonia      8
Ebstein's anomaly      182
ECG      see electrocardiogram
Economic analysis      308
Economic analysis, modelling as a tool for      313—315
Economic analysis, perspectives of      304—305
Edinburgh Postnatal Depression Scale      199
EEG      see electroencephalogram
Effexor $\textregistered$       11
Ego pain, somatization of      20
Ejaculation disorders      8 14
Elaril $\textregistered$       11
Elavil $\textregistered$       11
Electro-oculogram (EOG)      73
Electrocardiogram (ECG)      7—8
Electrocardiogram (ECG), safety markers in      163
Electroconvulsive therapy      133
Electroencephalogram (EEG)      70 77 80 84 86 89—92 95 324
Electroencephalogram (EEG) and elecmc potentials      74
Electroencephalogram (EEG), compared to functional imaging      208
Electroencephalogram (EEG), pharmaco-EEG studies      71—72 76 79 81 85 87 90 162 186—187
Electroencephalogram (EEG), pharmaco-EEG studies, advantages of      72
Electroencephalogram (EEG), pharmaco-EEG studies, topographic EEGs      72
Electroencephalogram (EEG), rhythms in man      73
Electroniyogram (EMG)      73
Electroshock      36 39 46 272
Elevated plus maze test      134—135
Eli Lilly      52—53
Elimination      see ADME
EMEA      see European Medicines Evaluation Agency
Emetic      28
EMG      see electromyogram
Endep $\textregistered$       11
Endocrine disorders, and dementia      253
Entacapone      126 313—315
Entacapone, five-year result model for      314
Enzymes      105
Enzymes, inhibition of degrading      126
EOG      see electro-oculogram
Epilepsy      29 31 38 307—308 313
EPS      see evoked potentials
EQ-5D instrument      307 316
ERPs      see event-related potentials
Escitalopram oxalate      11 14
Eskalith $\textregistered$       16
Esquirol, J.E.      34
Estazolam      19
Estrogen      161
Estrogen, therapy      311
Ethanol      see alcohol
Ether      34 59
Ethics      58
Ethics in clinical research      148—153
Ethics, medical      149
Ethoxyidazoxan      Plate 6.1
Euhynos $\textregistered$       19
Euphoria      10 20 24 185
European Medicines Evaluation Agency (EMEA)      148 303
European Medicines Evaluation Agency (EMEA), CPMP      169
Event-related potentials (ERPs)      74—77 80 84 86 94
Evoked potentials (EPs)      71 74—77 79—80 84—86 94 324
Evoked potentials (EPs), advantages of      72
Evoked potentials (EPs), odd-ball paradigms, and      75
Evoked potentials (EPs), visual      75
Excitement      20
Excretion      6
Executive function and motor performance      70
Executive function and motor performance, tests for      7/
Exelon $\textregistered$       26 53 96 255
Exhaustion      23
Eysenck, H.J.      97 323
Fatigue      2—3 14
Fatty acids, in functional imaging      209
Fear Questionnaire (FQ)      200
Fenfluramine      188
Ferrosan      53
Fick's Principle      215
Fink, M.      76
First-pass effect      158 160
Floropipamide      5
Fluanison      5
Fluanxol $\textregistered$       5
Fluid retention      17
Flumazenil      187—188
Flunitrazepam      19 243
Fluorine, $(^{18}F)$ in functional imaging      209 215
Fluorine, $(^{19}F)$ in MRI      211 225—226
Fluoxetine      10—11
Fluoxetine and bipolar disorder      276 279
Fluoxetine and OCD      23 292
Fluoxetine, action spectra of      12
Fluoxetine, brain metabolism and      217 225
Fluoxetine, discovery/introduction of      53 276
Fluoxetine, effects of      79—81 (80)
Fluoxetine, side effects of      14—15
Fluoxetine, specificity of      126 161
Fluoxetine, studies/trials of      167 172 192 238—239
Flupenthixol      5 267
Flupenthixol, effects of      77—78
Fluphenazine      5 6 225 263 267—268
Fluphenazine, decanoate      268
Flurazepam      19 242
Fluvoxamine      11
Fluvoxamine and OCD      23 292
Fluvoxamine, action spectra of      12
Fluvoxamine, discovery/introduction of      53 276
Fluvoxamine, effects of      81—82
Fluvoxamine, side effects of      14
Fluvoxamine, specificity of      161
Fluvoxamine, studies/trials of      293—294
FMRI      see magnetic resonance imaging functional
Food and Drug Administration, USA      16 23 45 148 163 169 279 303
Food effect      159
Forced swim test      132—133 138
Fourier transformation      212
FQ      see Fear Questionnaire
Freud, S.      323
Frisium $\textregistered$       19
Frontotemporal degeneration      253
Fuxe, K.      53
Gabapentin      16 241
GAD      see generalized anxiety disorder
Gadolinium (Gd) chelates      213
Galantamine      26 53—54 126 255—256
Galen      28 31
Gamma-amino-butyric acid (GABA)      110—111 124

1 2 3 4 5 6 7 8

О проекте